![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/21/2885553/37000/en/Organovo-Data-Presented-at-Digestive-Disease-Week-DDW2024-Demonstrating-Potential-for-FXR314-as-Combination-Therapy-with-Tofacitinib-for-Inflammatory-Bowel-Disease.html
https://www.globenewswire.com/news-release/2024/05/09/2878391/37000/en/Organovo-Holdings-Inc-Announces-Pricing-of-5-25-Million-Public-Offering.html
https://www.globenewswire.com//news-release/2024/01/09/2806254/37000/en/Organovo-To-Present-FXR314-IBD-3D-Model-Findings-at-Upcoming-Crohn-s-and-Colitis-Congress.html
https://www.globenewswire.com//news-release/2023/11/13/2779037/37000/en/CORRECTION-Organovo-Highlights-FXR314-Combination-Therapy-Potential-and-Plan.html
https://www.globenewswire.com//news-release/2023/09/08/2740276/37000/en/Organovo-to-Participate-in-the-H-C-Wainwright-Global-Investment-Conference.html
https://www.globenewswire.com//news-release/2023/08/23/2730387/37000/en/Organovo-Advances-Clinical-Timelines-for-FXR314-and-Provides-Updates-on-NASH-Phase-2-Data.html
https://www.globenewswire.com/news-release/2023/03/21/2631267/37000/en/Organovo-Announces-FXR-Program.html
https://www.globenewswire.com/news-release/2022/11/15/2556140/37000/en/Organovo-Announces-Target-Validation-Ahead-of-Schedule-Accelerating-Timeline-for-First-Crohn-s-Disease-Drug-Candidates.html
https://www.globenewswire.com/news-release/2022/09/06/2510390/37000/en/Organovo-to-Participate-in-the-H-C-Wainwright-24th-Annual-Global-Investment-Conference.html
https://www.globenewswire.com/news-release/2022/05/17/2444954/37000/en/Organovo-Achieves-3D-Tissue-Model-for-Crohn-s-Disease.html